Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.

The target antigen determines the mechanism of acquired resistance to T cell-based therapies

Autor: Alex Martínez-Sabadell, Beatriz Morancho, Irene Rius Ruiz, Macarena Román Alonso, Pablo Ovejero Romero, Marta Escorihuela, Irene Chicote, Hector G. Palmer, Lara Nonell, Mercè Alemany-Chavarria, Christian Klein, Marina Bacac, Joaquín Arribas, Enrique J. Arenas

Publikováno v: Scientia

Cancer; Antigen; Resistance Cáncer; Antígeno; Resistencia Càncer; Antigen; Resistència Despite the revolution of immunotherapy in cancer treatment, patients eventually progress due to the emergence of resistance. In this scenario, the selection o

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::cc127f0012885156478e5e44597d762d
https://pubmed.ncbi.nlm.nih.gov/36261015

p95HER2-T cell bispecific antibody for breast cancer treatment.

Autor: Rius Ruiz I; Preclinical Research Program, Vall d'Hebron Institute of Oncology (VHIO), 08035 Barcelona, Spain.; Centro de Investigación Biomédica en Red de Cáncer (CIBERONC), 08035 Barcelona, Spain., Vicario R; Preclinical Research Program, Vall d'Hebron Institute of Oncology (VHIO), 08035 Barcelona, Spain., Morancho B; Preclinical Research Program, Vall d'Hebron Institute of Oncology (VHIO), 08035 Barcelona, Spain.; Centro de Investigación Biomédica en Red de Cáncer (CIBERONC), 08035 Barcelona, Spain., Morales CB; Preclinical Research Program, Vall d'Hebron Institute of Oncology (VHIO), 08035 Barcelona, Spain.; Centro de Investigación Biomédica en Red de Cáncer (CIBERONC), 08035 Barcelona, Spain., Arenas EJ; Preclinical Research Program, Vall d'Hebron Institute of Oncology (VHIO), 08035 Barcelona, Spain., Herter S; Roche Innovation Center Zurich, Roche Pharmaceutical Research and Early Development, Wagistrasse 18, 8952 Schlieren, Switzerland., Freimoser-Grundschober A; Roche Innovation Center Zurich, Roche Pharmaceutical Research and Early Development, Wagistrasse 18, 8952 Schlieren, Switzerland., Somandin J; Roche Innovation Center Zurich, Roche Pharmaceutical Research and Early Development, Wagistrasse 18, 8952 Schlieren, Switzerland., Sam J; Roche Innovation Center Zurich, Roche Pharmaceutical Research and Early Development, Wagistrasse 18, 8952 Schlieren, Switzerland., Ast O; Roche Innovation Center Zurich, Roche Pharmaceutical Research and Early Development, Wagistrasse 18, 8952 Schlieren, Switzerland., Barriocanal ÁM; Preclinical Research Program, Vall d'Hebron Institute of Oncology (VHIO), 08035 Barcelona, Spain., Luque A; Preclinical Research Program, Vall d'Hebron Institute of Oncology (VHIO), 08035 Barcelona, Spain., Escorihuela M; Preclinical Research Program, Vall d'Hebron Institute of Oncology (VHIO), 08035 Barcelona, Spain., Varela I; Preclinical Research Program, Vall d'Hebron Institute of Oncology (VHIO), 08035 Barcelona, Spain., Cuartas I; Translational Research Program, VHIO, 08035 Barcelona, Spain., Nuciforo P; Clinical Research Program, VHIO, 08035 Barcelona, Spain., Fasani R; Clinical Research Program, VHIO, 08035 Barcelona, Spain., Peg V; Centro de Investigación Biomédica en Red de Cáncer (CIBERONC), 08035 Barcelona, Spain.; Vall d'Hebron University Hospital, 08035 Barcelona, Spain., Rubio I; Vall d'Hebron University Hospital, 08035 Barcelona, Spain., Cortés J; Clinical Research Program, VHIO, 08035 Barcelona, Spain., Serra V; Preclinical Research Program, Vall d'Hebron Institute of Oncology (VHIO), 08035 Barcelona, Spain.; Centro de Investigación Biomédica en Red de Cáncer (CIBERONC), 08035 Barcelona, Spain., Escriva-de-Romani S; Clinical Research Program, VHIO, 08035 Barcelona, Spain.; Vall d'Hebron University Hospital, 08035 Barcelona, Spain., Sperinde J; Monogram Biosciences, Laboratory Corporation of America Holdings, South San Francisco, CA 94080, USA., Chenna A; Monogram Biosciences, Laboratory Corporation of America Holdings, South San Francisco, CA 94080, USA., Huang W; Monogram Biosciences, Laboratory Corporation of America Holdings, South San Francisco, CA 94080, USA., Winslow J; Monogram Biosciences, Laboratory Corporation of America Holdings, South San Francisco, CA 94080, USA., Albanell J; Centro de Investigación Biomédica en Red de Cáncer (CIBERONC), 08035 Barcelona, Spain.; Cancer Research Program, IMIM (Hospital del Mar Medical Research Institute), 08003 Barcelona, Spain.; Medical Oncology Service, Hospital del Mar, 08003 Barcelona, Spain.; Universitat Pompeu Fabra, 08003 Barcelona, Spain., Seoane J; Centro de Investigación Biomédica en Red de Cáncer (CIBERONC), 08035 Barcelona, Spain.; Translational Research Program, VHIO, 08035 Barcelona, Spain.; Department of Biochemistry and Molecular Biology, Universitat Autónoma de Barcelona, Campus de la UAB, 08193 Bellaterra, Spain.; Institució Catalana de Recerca i Estudis Avançats, 08010 Barcelona, Spain., Scaltriti M; Department of Pathology, Human Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA., Baselga J; Department of Medicine, Human Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA., Tabernero J; Centro de Investigación Biomédica en Red de Cáncer (CIBERONC), 08035 Barcelona, Spain.; Clinical Research Program, VHIO, 08035 Barcelona, Spain.; Vall d'Hebron University Hospital, 08035 Barcelona, Spain., Umana P; Roche Innovation Center Zurich, Roche Pharmaceutical Research and Early Development, Wagistrasse 18, 8952 Schlieren, Switzerland., Bacac M; Roche Innovation Center Zurich, Roche Pharmaceutical Research and Early Development, Wagistrasse 18, 8952 Schlieren, Switzerland., Saura C; Clinical Research Program, VHIO, 08035 Barcelona, Spain.; Vall d'Hebron University Hospital, 08035 Barcelona, Spain., Klein C; Roche Innovation Center Zurich, Roche Pharmaceutical Research and Early Development, Wagistrasse 18, 8952 Schlieren, Switzerland., Arribas J; Preclinical Research Program, Vall d'Hebron Institute of Oncology (VHIO), 08035 Barcelona, Spain. jarribas@vhio.net.; Centro de Investigación Biomédica en Red de Cáncer (CIBERONC), 08035 Barcelona, Spain.; Department of Biochemistry and Molecular Biology, Universitat Autónoma de Barcelona, Campus de la UAB, 08193 Bellaterra, Spain.; Institució Catalana de Recerca i Estudis Avançats, 08010 Barcelona, Spain.

Publikováno v: Science translational medicine [Sci Transl Med] 2018 Oct 03; Vol. 10 (461).